AP2013006986A0 - Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) - Google Patents

Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)

Info

Publication number
AP2013006986A0
AP2013006986A0 AP2013006986A AP2013006986A AP2013006986A0 AP 2013006986 A0 AP2013006986 A0 AP 2013006986A0 AP 2013006986 A AP2013006986 A AP 2013006986A AP 2013006986 A AP2013006986 A AP 2013006986A AP 2013006986 A0 AP2013006986 A0 AP 2013006986A0
Authority
AP
ARIPO
Prior art keywords
amd
analogues
age
useful
treatment
Prior art date
Application number
AP2013006986A
Other languages
English (en)
Inventor
Eva Altmann
Ulrich Hommel
Edwidge Liliane Jeanne Lorthiois
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013006986(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2013006986A0 publication Critical patent/AP2013006986A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
AP2013006986A 2011-01-04 2012-01-02 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) AP2013006986A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161429730P 2011-01-04 2011-01-04
PCT/EP2012/050005 WO2012093101A1 (en) 2011-01-04 2012-01-02 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)

Publications (1)

Publication Number Publication Date
AP2013006986A0 true AP2013006986A0 (en) 2013-07-31

Family

ID=45464587

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006986A AP2013006986A0 (en) 2011-01-04 2012-01-02 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)

Country Status (28)

Country Link
US (1) US9085555B2 (es)
EP (1) EP2661433B1 (es)
JP (1) JP5921572B2 (es)
KR (1) KR20140027090A (es)
CN (1) CN103402996B (es)
AP (1) AP2013006986A0 (es)
AR (1) AR084768A1 (es)
AU (1) AU2012204920B2 (es)
BR (1) BR112013017316A2 (es)
CA (1) CA2823665A1 (es)
CL (1) CL2013001891A1 (es)
CO (1) CO6791608A2 (es)
CR (1) CR20130333A (es)
CU (1) CU20130094A7 (es)
EA (1) EA023259B1 (es)
ES (1) ES2647664T3 (es)
GT (1) GT201300174A (es)
MA (1) MA34837B1 (es)
MX (1) MX347391B (es)
PE (1) PE20140471A1 (es)
PL (1) PL2661433T3 (es)
PT (1) PT2661433T (es)
SG (1) SG191844A1 (es)
TN (1) TN2013000275A1 (es)
TW (1) TW201242959A (es)
UY (1) UY33858A (es)
WO (1) WO2012093101A1 (es)
ZA (1) ZA201304684B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867227B1 (en) * 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
JP6273274B2 (ja) * 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP2015522007A (ja) * 2012-06-28 2015-08-03 ノバルティス アーゲー ピロリジン誘導体、および補体経路モジュレーターとしてのその使用
CN104619698B (zh) * 2012-06-28 2016-08-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
ES2648962T3 (es) * 2012-06-28 2018-01-09 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la vía del complemento
EP2867224B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
WO2014005150A1 (en) * 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
WO2014002059A1 (en) * 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
EA201590200A1 (ru) * 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
ES2904321T3 (es) * 2012-07-27 2022-04-04 Sato Pharma Procedimiento para preparar compuestos de difluorometileno
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN104341360A (zh) * 2013-07-31 2015-02-11 南京长澳医药科技有限公司 一种卢非酰胺的制备方法
WO2015031903A1 (en) * 2013-09-02 2015-03-05 Paul Reid Novel skin care formulation
JPWO2015060368A1 (ja) 2013-10-23 2017-03-09 武田薬品工業株式会社 複素環化合物
EP2883876A1 (en) 2013-12-16 2015-06-17 Actelion Pharmaceuticals Ltd. Stereoselective synthesis of substituted pyrrolidines
AP2016009434A0 (en) * 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Amide compounds for treatment of complement mediated disorders
EA202191781A1 (ru) * 2014-09-05 2021-09-03 Ачиллион Фармасьютикалс, Инк. Арильные, гетероарильные и гетероциклические соединения для лечения опосредованных комплементом расстройств
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) * 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035417A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035352A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035413A2 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035348A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
AR105808A1 (es) * 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035411A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035361A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
US20190127366A1 (en) * 2015-12-11 2019-05-02 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
MA55194A (fr) 2015-12-22 2022-05-04 Incyte Corp Composés hétérocycliques en tant qu'immunomodulateurs
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
CN108699105A (zh) 2016-03-04 2018-10-23 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
CN108699106B (zh) 2016-03-04 2021-11-30 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018015818A2 (en) * 2016-07-15 2018-01-25 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3484859B1 (en) 2016-07-18 2021-09-15 F. Hoffmann-La Roche AG New difluoroketamide derivatives as htra1 inhibitors
JP2019526564A (ja) 2016-08-23 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
EP3504193A1 (en) 2016-08-23 2019-07-03 H. Hoffnabb-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
TW202241895A (zh) 2016-09-09 2022-11-01 美商英塞特公司 吡唑并吡啶化合物及其用途
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN106588818B (zh) * 2016-11-30 2019-07-26 兰州大学 一种医药中间体2,6-二氟-3-吗啉苯基甲胺及其制备方法
CN108203434B (zh) * 2016-12-20 2022-02-25 中国科学院上海药物研究所 一种制备索利那新的不对称合成方法
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
IL313101A (en) 2018-03-30 2024-07-01 Incyte Corp Heterocyclic compounds as immunomodulators
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
PT3790877T (pt) 2018-05-11 2023-05-10 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
MX2021003425A (es) * 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
KR20210104071A (ko) * 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
MX2022001671A (es) 2019-08-09 2022-05-13 Incyte Corp Sales de un inhibidor de pd-1/pd-l1.
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
EP4107166A4 (en) * 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
AR121715A1 (es) * 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
KR20230009431A (ko) 2020-05-12 2023-01-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
CN112898273B (zh) * 2021-03-30 2022-05-31 海南锦瑞制药有限公司 伏立康唑的合成方法及应用
CN113372223B (zh) * 2021-05-20 2022-10-28 宁波职业技术学院 一种2-氟-3-溴-苄胺的制备方法
EP4362933A1 (en) * 2021-06-30 2024-05-08 Apellis Pharmaceuticals, Inc. Complement inhibition
EP4419097A1 (en) * 2021-10-18 2024-08-28 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy
EP4174077A1 (en) * 2021-10-27 2023-05-03 Merck Patent GmbH Electronic switching device
CN114105790A (zh) * 2021-12-14 2022-03-01 无锡捷化医药科技有限公司 一种3-氨基-4,5-二溴苯甲酸甲酯的制备方法
CA3239230A1 (en) * 2021-12-15 2023-06-22 Akihiro Hashimoto Methods for the synthesis of complement factor d inhibitors
WO2023182871A1 (ko) * 2022-03-25 2023-09-28 바스테라 주식회사 3-페닐이속사졸 유도체 및 이를 유효성분으로 함유하는 안질환 예방 또는 치료용 약학 조성물
WO2023200364A1 (ru) * 2022-04-15 2023-10-19 Общество С Ограниченной Ответственностью "Промомед Рус" Способы получения (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
CA2120956A1 (en) 1992-09-03 1994-03-17 Franz Esser New amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9815881A (pt) 1998-06-03 2002-07-23 Gpi Nil Holding Inc Uréias e carbamatos de ácido carboxìlicos n-heterocìclicos e isoésteres de ácido carboxìlico
WO1999062487A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
AU764032B2 (en) 1998-06-03 2003-08-07 Gpi Nil Holdings, Inc. Small molecule carbamate or urea hair growth compositions and uses
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
CA2426271A1 (en) 2000-10-19 2002-04-25 Naeja Pharmaceutical Inc. Dihydropyrimidine derivatives as cysteine protease inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
NL1021590C1 (nl) 2002-10-05 2004-04-06 Johannes Antonius Josep Visser Oogstinrichting voor het oogsten van gewassen en sorteerinrichting.
JP2006510742A (ja) 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
CA2512582C (en) 2003-01-08 2014-07-08 University Of Washington Antibacterial agents
WO2004062607A2 (en) 2003-01-13 2004-07-29 Ying Zhang Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
DE502004009440D1 (de) 2003-04-03 2009-06-10 Merck Patent Gmbh Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
DK1856102T3 (da) 2005-02-28 2009-08-31 Tseti Ioulia Medikamenter til Alzheimers sygdom
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1888563A1 (en) 2005-05-23 2008-02-20 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
AU2006275413B2 (en) 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2625206C (en) 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
HUE026496T2 (en) 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
PL2049478T3 (pl) * 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
EP2907827B1 (en) 2006-11-02 2018-09-19 Genentech, Inc. Humanized anti-factor D antibodies and uses thereof
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
EP1988098A1 (en) 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2009106980A2 (en) * 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
PT2331547E (pt) 2008-08-22 2014-10-29 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
EA201391000A1 (ru) 2013-12-30
JP5921572B2 (ja) 2016-05-24
CO6791608A2 (es) 2013-11-14
SG191844A1 (en) 2013-08-30
US20120295884A1 (en) 2012-11-22
EP2661433B1 (en) 2017-08-16
CU20130094A7 (es) 2013-10-29
CL2013001891A1 (es) 2014-09-05
WO2012093101A1 (en) 2012-07-12
PL2661433T3 (pl) 2018-01-31
CN103402996B (zh) 2015-02-11
NZ612899A (en) 2015-07-31
MX2013007867A (es) 2013-07-17
PT2661433T (pt) 2017-10-24
ES2647664T3 (es) 2017-12-26
AR084768A1 (es) 2013-06-26
US9085555B2 (en) 2015-07-21
CA2823665A1 (en) 2012-07-12
MA34837B1 (fr) 2014-01-02
GT201300174A (es) 2014-06-06
EA023259B1 (ru) 2016-05-31
KR20140027090A (ko) 2014-03-06
MX347391B (es) 2017-04-25
TN2013000275A1 (en) 2014-11-10
AU2012204920A1 (en) 2013-07-18
TW201242959A (en) 2012-11-01
CR20130333A (es) 2013-09-04
EP2661433A1 (en) 2013-11-13
UY33858A (es) 2012-08-31
CN103402996A (zh) 2013-11-20
ZA201304684B (en) 2014-03-26
BR112013017316A2 (pt) 2019-09-24
JP2014506877A (ja) 2014-03-20
AU2012204920B2 (en) 2014-08-07
PE20140471A1 (es) 2014-04-13

Similar Documents

Publication Publication Date Title
ZA201304684B (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
HK1197400A1 (zh) 治療 的化合物
AP3544A (en) Compounds for the treatment of addiction
HK1201042A1 (en) Compositions for the treatment of dry eye
IL230830A0 (en) Cellular preparations for the treatment of degenerative diseases of the retina
EP2773342A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
HK1199649A1 (en) Process for the preparation of polyamides
SG11201400939YA (en) Process for the preparation of methoxymelonal
ZA201403736B (en) Process for the preparation of sterol derivatives
IL231593B (en) Buprenorphine for the treatment of acute suicidality
EP2780348A4 (en) PROCESS FOR THE PRODUCTION OF TENOFOVIR
EP2688875A4 (en) METHOD FOR PRODUCING S-TRIAZIN COMPOUNDS
EP2692345A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MACULAR DEGENERATION
GB201119690D0 (en) Process for the preparation of compounds
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
PL393916A1 (pl) Sposób wytwarzania związków karbapenamowych
PT2777699T (pt) Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
EP2661279A4 (en) METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION
ZA201309732B (en) Process for the preparation of dexlansoprazole
PL394420A1 (pl) Sposób wytwarzania dilauroilofluoresceiny
PL394378A1 (pl) Sposób otrzymywania E-2-amino-4-nitrostilbenów